VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: VLAD who wrote (19939)	3/21/1999 5:32:00 PM
From: VLAD	of 23519

Thought I would make this post for those investors new to Vivus and wanting a little more scientific information. Some are abstracts for quicker reading and some are from Vivus' own press release archives and are listed in order of oldest releases to most recent: vivus.com ncbi.nlm.nih.gov vivus.com vivus.com vivus.com vivus.com ncbi.nlm.nih.gov ncbi.nlm.nih.gov vivus.com vivus.com vivus.com vivus.com vivus.com ncbi.nlm.nih.gov vivus.com vivus.com ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov So that I am not accused of being too biased towards MUSE there are articles published that demonstrates that IC administered alprostidal produces more rigid and longer lasting erections. Nobody here debates this fact but the fact is that it must be delivered with a metal needle which is much less acceptable by the patient and can more readily lead to penile scaring and priapism(prolonged erections that can last for hours whereas a MUSE erection lasts for 30 to 60 minutes) the use of the Actis band certainly improves the quality of erections using MUSE. Also, our new product Alibra has fewer side effects, has greater efficacy and will be cheaper to produce and doesn't require refrigeration. Finally, the one study that was presented at last years AAU meeting which was a small biased and poorly conducted study that the shorts certainly gave good press to and Vivus was slow in responding towards: ncbi.nlm.nih.gov and Vivus' response: vivus.com I might add that the way the shorts capitalized on touting the Fulgham study and Vivus' slow response resulted in long lasting technical damage to Vivus stock price as it traded below 8 and never was able to show any significant recover. Fulgham did not challenge the failures on the highest and most commonly used 1000ugm dose and Actis was not used in his study. This information all focuses on Vivus' primary product MUSE which still has a long ways to go regarding global marketing. I might also mention that our better and more effective second generation product Alibra will be ready for NDA submission to the FDA in Q3 1999. We will learn more about Vivus female SD product in the near future. Vivus also has just bought the rights to a new drug. I do not know what the drug is or does but I have confirmation of this fact and we probably will learn more about it in early April's conference call. Also, expect that even without any more milestones Vivus will show at LEAST a 1 cent/share profit. Product sales will not be good but this is to be expected as we still don't have a domestic partner and international demand has been on hold as Astra has still not begun its full European launch which will soon occur.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next